iBio Inc [IBIO] stock is trading at $0.91, down -7.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IBIO shares have gain 11.39% over the last week, with a monthly amount glided 10.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
iBio Inc [NASDAQ: IBIO] stock has seen the most recent analyst activity on May 28, 2024, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $5. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on November 29, 2021, and set its price target to $1.50. On January 22, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $3 on the stock. Alliance Global Partners started tracking the stock assigning a Buy rating and suggested a price target of $2.55 on June 26, 2020.
iBio Inc [IBIO] stock has fluctuated between $0.64 and $6.89 over the past year. Currently, Wall Street analysts expect the stock to reach $3.6 within the next 12 months. iBio Inc [NASDAQ: IBIO] shares were valued at $0.91 at the most recent close of the market. An investor can expect a potential return of 295.6% based on the average IBIO price forecast.
Analyzing the IBIO fundamentals
Gross Profit Margin for this corporation currently stands at 2.98% with Operating Profit Margin at -44.83%, Pretax Profit Margin comes in at -43.89%, and Net Profit Margin reading is -55.98%. To continue investigating profitability, this company’s Return on Assets is posted at -1.1, Equity is -1.3 and Total Capital is -1.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8530 points at the first support level, and at 0.7915 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9730, and for the 2nd resistance point, it is at 1.0315.
Ratios To Look Out For
For context, iBio Inc’s Current Ratio is 1.12. In addition, the Quick Ratio stands at 1.12 and the Cash Ratio stands at 0.92. Considering the valuation of this stock, the price to sales ratio is 39.76, the price to book ratio is 0.81.
Transactions by insiders
Recent insider trading involved Duran Felipe, Chief Financial Officer, that happened on Jan 10 ’25 when 9191.0 shares were purchased., Brenner Martin completed a deal on Jan 10 ’25 to buy 9191.0 shares. Meanwhile, Chief Legal Officer Banjak Marc bought 9191.0 shares on Jan 10 ’25.
